Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-Current Deferred Tax Liability (2017 - 2023)

Aclaris Therapeutics (ACRS) has 7 years of Non-Current Deferred Tax Liability data on record, last reported at $367000.0 in Q3 2023.

  • For Q3 2023, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $367000.0; the TTM value through Sep 2023 reached $367000.0, changed 0.0%, while the annual FY2022 figure was $367000.0, 0.0% changed from the prior year.
  • Non-Current Deferred Tax Liability reached $367000.0 in Q3 2023 per ACRS's latest filing, roughly flat from $367000.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $549000.0 in Q1 2019 and bottomed at $367000.0 in Q4 2020.
  • Average Non-Current Deferred Tax Liability over 5 years is $434052.6, with a median of $367000.0 recorded in 2020.
  • Peak YoY movement for Non-Current Deferred Tax Liability: changed 0.0% in 2019, then tumbled 33.15% in 2020.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $549000.0 in 2019, then crashed by 33.15% to $367000.0 in 2020, then changed by 0.0% to $367000.0 in 2021, then changed by 0.0% to $367000.0 in 2022, then changed by 0.0% to $367000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Non-Current Deferred Tax Liability were $367000.0 in Q3 2023, $367000.0 in Q2 2023, and $367000.0 in Q1 2023.